Patient-derived models facilitate precision medicine in liver cancer by remodeling cell-matrix interaction

Kaiwen Chen; Yanran Li; Bingran Wang; Xuehan Yan; Yiying Tao; Weizhou Song; Zhifeng Xi; Kang He; Qiang Xia

doi:10.3389/fimmu.2023.1101324

Patient-derived models facilitate precision medicine in liver cancer by remodeling cell-matrix interaction

Front Immunol. 2023 May 4:14:1101324. doi: 10.3389/fimmu.2023.1101324. eCollection 2023.

Authors

Kaiwen Chen^{1

2

3}, Yanran Li^{1

2

3}, Bingran Wang^{1

2

3}, Xuehan Yan⁴, Yiying Tao⁵, Weizhou Song⁶, Zhifeng Xi^{1

2

3}, Kang He^{1

2

3}, Qiang Xia^{1

2

3}

Affiliations

¹ Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² Shanghai Engineering Research Center of Transplantation and Immunology, Shanghai, China.
³ Shanghai Institute of Transplantation, Shanghai, China.
⁴ Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁵ Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁶ Ottawa-Shanghai Joint School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Abstract

Liver cancer is an aggressive tumor originating in the liver with a dismal prognosis. Current evidence suggests that liver cancer is the fifth most prevalent cancer worldwide and the second most deadly type of malignancy. Tumor heterogeneity accounts for the differences in drug responses among patients, emphasizing the importance of precision medicine. Patient-derived models of cancer are widely used preclinical models to study precision medicine since they preserve tumor heterogeneity ex vivo in the study of many cancers. Patient-derived models preserving cell-cell and cell-matrix interactions better recapitulate in vivo conditions, including patient-derived xenografts (PDXs), induced pluripotent stem cells (iPSCs), precision-cut liver slices (PCLSs), patient-derived organoids (PDOs), and patient-derived tumor spheroids (PDTSs). In this review, we provide a comprehensive overview of the different modalities used to establish preclinical models for precision medicine in liver cancer.

Keywords: cell-matrix interaction; liver cancer; patient derived models; precision medicine; tumor models.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Disease Models, Animal
Humans
Induced Pluripotent Stem Cells*
Liver Neoplasms* / pathology
Liver Neoplasms* / therapy
Organoids
Precision Medicine

Grants and funding

This study was supported by the Project of the Shanghai Municipal Health Commission (20204Y0012), the Seed Fund of Renji Hospital (RJZZ18-010), the Shenkang three-year action plan (SHDC2020CR2003A, SHDC2020CR5012), and the Project of Shanghai key clinical specialties (shslczdzk05801).